Fresenius Medical Care Corporation (FMS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Fresenius Medical Care Corporation stock (FMS) is currently trading at $22.03. Fresenius Medical Care Corporation PE ratio is 11.21. Fresenius Medical Care Corporation PS ratio (Price-to-Sales) is 0.64. Analyst consensus price target for FMS is $27.21. WallStSmart rates FMS as Hold.
- FMS PE ratio analysis and historical PE chart
- FMS PS ratio (Price-to-Sales) history and trend
- FMS intrinsic value — DCF, Graham Number, EPV models
- FMS stock price prediction 2025 2026 2027 2028 2029 2030
- FMS fair value vs current price
- FMS insider transactions and insider buying
- Is FMS undervalued or overvalued?
- Fresenius Medical Care Corporation financial analysis — revenue, earnings, cash flow
- FMS Piotroski F-Score and Altman Z-Score
- FMS analyst price target and Smart Rating
Fresenius Medical Care Corporation
📊 No data available
Try selecting a different time range
FMS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Fresenius Medical Care Corporation (FMS)
FMS trades at a significant discount to its Graham intrinsic value of $90.32, offering a 73% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Fresenius Medical Care Corporation (FMS) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/sales. Concerns around return on equity and revenue growth. Fundamentals are solid but monitor weak areas for improvement.
Fresenius Medical Care Corporation (FMS) Key Strengths (5)
Growing significantly faster than its price suggests
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
Earnings per share surging 420.00% year-over-year
Large-cap company with substantial market presence
Supporting Valuation Data
Fresenius Medical Care Corporation (FMS) Areas to Watch (5)
Revenue declining -0.30%, a shrinking business
Very thin margins, barely profitable
Very low institutional interest at 8.57%
Low profitability relative to shareholder equity
Thin operating margins with cost pressures present
Fresenius Medical Care Corporation (FMS) Detailed Analysis Report
Overall Assessment
This company scores 62/100 in our Smart Analysis, earning a C+ grade. Out of 10 metrics analyzed, 5 register as strengths (avg 9.8/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Price/Sales, Price/Book. Valuation metrics including PEG Ratio (0.73), Price/Sales (0.64), Price/Book (0.79) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 420.00%.
The Bear Case
The primary concerns are Revenue Growth, Profit Margin, Institutional Own.. Growth concerns include Revenue Growth at -0.30%, which may limit upside. Profitability pressure is visible in Return on Equity at 7.93%, Operating Margin at 11.70%, Profit Margin at 4.99%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Revenue Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 7.93% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -0.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. Strengths and concerns are roughly balanced. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Price/Sales) and negatives (Revenue Growth, Profit Margin). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
FMS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
FMS's Price-to-Sales ratio of 0.64x trades at a deep discount to its historical average of 2.92x (0th percentile). The current valuation is 88% below its historical high of 5.13x set in Jul 2011, and -1% above its historical low of 0.64x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Fresenius Medical Care Corporation (FMS) · HEALTHCARE › MEDICAL CARE FACILITIES
The Big Picture
Fresenius Medical Care Corporation faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 19.6B with 30% decline year-over-year. Profit margins are strong at 499.0%, reflecting pricing power and operational efficiency.
Key Findings
ROE of 793.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Generating 564M in free cash flow and 975M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 30% YoY. Worth determining whether this is cyclical or structural.
What to Watch Next
Dividend sustainability with a current yield of 377.0%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 10.5B is significantly higher than cash (1.3B). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL CARE FACILITIES industry trends, competitive moves, and regulatory changes that could impact Fresenius Medical Care Corporation.
Bottom Line
Fresenius Medical Care Corporation faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Fresenius Medical Care Corporation(FMS)
NYSE
HEALTHCARE
MEDICAL CARE FACILITIES
USA
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America and internationally. The company is headquartered in Bad Homburg, Germany.